Patients who develop COVID-19 coagulopathies are characterized by the presence of multiple autoantibodies against blood-related autoantigens, including cardiolipin (CL), beta 2 glycoprotein I (β2GPI), platelet factor 4 (PF4) and usually one or more coagulation factors such as Factor 2 (prothrombin), von Willebrand Factor (vWF), Fact VIII and/or Factor X, whereas patients testing positive for only one of these autoantibodies do not develop coagulopathies (reviewed in [69,70]). This evidence concerns the gene F2 and COVID-19.